Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash	$ 97,906	$ 568,769
Restricted cash	20,000	20,000
Accounts receivable	19,748	19,748
Prepaid & other current assets	20,682	18,778
Total current assets	158,336	627,295
Intangibles, net of accumulated amortization of $201,180 and $188,339	809,000	821,841
In process R&D	1,101,760	1,101,760
Goodwill	21,062,455	21,062,455
Total assets	23,131,551	23,613,351
Current liabilities:
Accounts payable and accrued liabilities	3,525,102	3,092,723
Accounts payable to related party	358,074	403,423
Contingent consideration	2,625,000	2,625,000
Derivative liability on Notes	531,131	340,290
Convertible and short-term debt, net of costs	8,931,916	8,166,622
Convertible debt and short-term debt, related party, net of costs	837,737	826,862
Total current liabilities	16,808,960	15,454,920
Commitments and contingencies (Note 13)
Stockholders’ equity:
Convertible preferred stock, $0.01 par value, 15,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $.01 par value; 750,000,000 shares authorized; 378,630,104 and 375,288,146 issued and outstanding, respectively	3,786,301	3,752,881
Additional paid-in capital	38,444,903	35,223,842
Accumulated deficit	(35,870,831)	(31,021,050)
Total Oncotelic Therapeutics, Inc. stockholders’ equity	6,360,373	7,955,673
Non-controlling interests	(37,782)	202,758
Total stockholders’ equity	6,322,591	8,158,431
Total liabilities and stockholders’ equity	$ 23,131,551	$ 23,613,351